title: Is it possible to prevent bacterial adhesion onto ureteric stents?
abstract: The aim of this study was to determine whether the use of bactericidal coatings or immersion in antibiotic solution reduces or prevents bacterial adhesion onto ureteric stents. Precut segments of full silicone, silver-coated and hydrogel-coated ureteric stents were incubated with two uropathogenic bacterial strains with and without previous immersion in antibiotic solution. Tobramycin, ceftriaxone and ciprofloxacin solutions were used, as these antibiotics are commonly administered for the prophylaxis and treatment of urinary tract infection (UTI). Microbiological analysis showed that immersion of ureteric stents in ceftriaxone and ciprofloxacin yielded a significant reduction of bacterial adhesion, whereas immersion in tobramycin did not. The surface material of the stents had no direct influence on bacterial adhesion. In this experimental study, neither the silver nor the hydrogel coat reduced bacterial adhesion onto ureteric stents whereas immersion in a suitable antibiotic solution significantly reduced and even prevented this phenomenon, probably due to the adhesion of the antibiotic onto the stent surface. Prevention of bacterial adhesion onto ureteric stents is essential to reduce the risk of UTI in connection with these devices.
authors.affiliation: Department of Urology, Helsinki University Central Hospital, Finland.
authors.forename: L
authors.initials: L
authors.lastname: Cormio
authors.forename: P
authors.initials: P
authors.lastname: La Forgia
authors.forename: D
authors.initials: D
authors.lastname: La Forgia
authors.forename: A
authors.initials: A
authors.lastname: Siitonen
authors.forename: M
authors.initials: M
authors.lastname: Ruutu
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology; D001422:Bacterial Adhesion / Q000187:drug effects*; D001431:Bacteriological Techniques; D002443:Ceftriaxone / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D004926:Escherichia coli; D006801:Humans; D008422:Materials Testing; D015607:Stents / Q000009:adverse effects*; D014031:Tobramycin / Q000494:pharmacology; D014513:Ureter / Q000382:microbiology / Q000601:surgery*; D014552:Urinary Tract Infections / Q000517:prevention & control*
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D002939:Ciprofloxacin; D002443:Ceftriaxone; D014031:Tobramycin